Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
Open Access
- 9 September 2011
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 12 (9), 5815-5827
- https://doi.org/10.3390/ijms12095815
Abstract
Aims: The relationship between variants in SLCO1B1 and SLCO2B1 genes and lipid-lowering response to atorvastatin was investigated. Material and Methods: One-hundred-thirty-six unrelated individuals with hypercholesterolemia were selected and treated with atorvastatin (10 mg/day/4 weeks). They were genotyped with a panel of ancestry informative markers for individual African component of ancestry (ACA) estimation by SNaPshot® and SLCO1B1 (c.388A>G, c.463C>A and c.521T>C) and SLCO2B1 (−71T>C) gene polymorphisms were identified by TaqMan® Real-time PCR. Results: Subjects carrying SLCO1B1 c.388GG genotype exhibited significantly high low-density lipoprotein (LDL) cholesterol reduction relative to c.388AA+c.388AG carriers (41 vs. 37%, p = 0.034). Haplotype analysis revealed that homozygous of SLCO1B1*15 (c.521C and c.388G) variant had similar response to statin relative to heterozygous and non-carriers. A multivariate logistic regression analysis confirmed that c.388GG genotype was associated with higher LDL cholesterol reduction in the study population (OR: 3.2, CI95%:1.3–8.0, p < 0.05). Conclusion: SLCO1B1 c.388A>G polymorphism causes significant increase in atorvastatin response and may be an important marker for predicting efficacy of lipid-lowering therapy.This publication has 40 references indexed in Scilit:
- Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of StatinsCirculation Research, 2010
- OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteersJournal of Clinical Pharmacy & Therapeutics, 2010
- SLCO1B1 variants and statin-induced myopathy - A genomewide studyThe New England Journal of Medicine, 2008
- Organic anion transporting polypeptide-1B1 haplotypes in Chinese patientsActa Pharmacologica Sinica, 2007
- SLCO1B1 521T→C functional genetic polymorphism and lipid‐lowering efficacy of multiple‐dose pravastatin in Chinese coronary heart disease patientsBritish Journal of Clinical Pharmacology, 2007
- Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapyJournal of Human Genetics, 2006
- Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genesBritish Journal of Clinical Pharmacology, 2006
- An association study of 43 SNPs in 16 candidate genes with atorvastatin responseThe Pharmacogenomics Journal, 2005
- High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)Pharmacogenetics, 2004
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995